Summary Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Net cash flows from operating activities:
Net income	$ 3,977	$ 4,325
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	2,940	2,735
Non-cash compensation	1,558	1,496
Deferred income taxes	474	1,264
Other non-cash adjustments to income	791	457
Changes in operating assets and liabilities:
Receivables	(2,279)	(6,711)
Deferred preservation costs and inventories	(259)	(1,293)
Prepaid expenses and other assets	(1,116)	(1,256)
Accounts payable, accrued expenses, and other liabilities	(2,051)	3,911
Net cash flows provided by operating activities	4,035	4,928
Net cash flows from investing activities:
Acquisition of Hemosphere, net of cash acquired		(17,055)
Capital expenditures	(2,257)	(1,548)
Other	(115)	(723)
Net cash flows used in investing activities	(2,372)	(19,326)
Net cash flows from financing activities:
Cash dividends paid	(1,443)
Proceeds from exercise of stock options and issuance of common stock	242	146
Repurchases of common stock	(1,378)	(3,389)
Other	(406)	(74)
Net cash flows used in financing activities	(2,985)	(3,317)
Decrease in cash and cash equivalents	(1,322)	(17,715)
Effect of exchange rate changes on cash	45	9
Cash and cash equivalents, beginning of period	13,009	21,705
Cash and cash equivalents, end of period	$ 11,732	$ 3,999